MarketInOut Stock Screener Log In | Sign Up
 

UCB S.A. ADR

OTC • Healthcare • Biotechnology • Quote as of 08/25/2026 15:58
UCB S.A. ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization46,750 mln
Float240 mln
Earnings Date02/25/2027

EPS

6.52
Strong

P / E

20.03
Premium valuation

Piotroski F-Score

9 / 9
Exceptional

Beneish M-Score

-2.49
Borderline

1-Year Forecast

165
Strong upside

Relative Strength

47 / 100
In line with market

Business Description

UCB SA is a Belgian biopharmaceutical company founded in 1925 and headquartered in Brussels, focused on developing medicines for people living with neurological and immune system conditions. Its portfolio includes established treatments for epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, and osteoporosis, among other serious conditions. The company is also advancing a pipeline of new therapies targeting Alzheimer's disease, lupus, and several rare genetic disorders. In addition to its research and commercial activities, UCB provides contract manufacturing services.

Key Fundamentals

EPS6.52
P/E20.03
ROE20.48
RPS25.55
ROIC17.09
ROA11.79
Interest Cover29.19
EBITDA, mln3,777
EV / EBITDA12.88
EV / EBIT15.95
Revenue, mln9,901
EV / Revenue4.91

Financial Strength

Altman Z-Score5.41
Piotroski F-Score 9 / 9
Beneish M-Score-2.49
Price to Lynch Fair Value2.17
Price to Graham Number8.73
1-Year Target Price165
Shiller PE Ratio32.18

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 3.83% 66 / 100   
1 Month -6.26% 20 / 100   
2 Months -2.44% 43 / 100   
6 Months -17.65% 30 / 100   
1 Year 13.55% 52 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us